论文部分内容阅读
青紫霉素是1970年由日本兴和株式会社东京研究所研制的新抗生素,其产生菌是从土壤中分离到的淡紫青链霉菌(Streptomy-ces lividus )n—sp,ATCC21178,青紫霉素的分子式是C_(29)H_(55)N_5O_(18),并观察了它对结核菌的抗菌作用,随后宝来等(1971)、五味等(1971)和山本等(1972)也对它的抗结核作用进行了研究。1974 -1975年,我国的青紫霉素由上海医药工业研究院研制成功。1979年我们用此药进行抗结核作用的研究。 一、试管内抑菌作用 材料和方法 药物:实验用的青紫霉素是由上海医药工业研究院提供的,批号770423,对照用药有异菸肼,甲哌力复霉素(利福平)和异丁基哌嗪力复霉素,按所稀释浓度分别放入灭菌的瓦氏管内。 培养基:采用改良苏通半流体培养基,制备后分别加入含药的瓦氏管内。
Qingomycin is a new antibiotic developed by Japan Hing Co., Ltd. and Tokyo Research Institute Co., Ltd. in 1970. Its producing bacteria are Streptomyces cv. Lividus n-sp, ATCC21178, The molecular formula is C_ (29) H_ (55) N_5O_ (18), and its antibacterial activity against Mycobacterium tuberculosis was observed. Subsequently, Polaris et al. (1971), Wuwei et al. Tuberculosis has been studied. From 1974 to 1975, China’s Qingzimycin was successfully developed by Shanghai Institute of Pharmaceutical Industry. In 1979 we used the drug for anti-TB study. First, the antibacterial effect in vitro Materials and Methods Drugs: Experimental Qingzimycin is provided by the Shanghai Institute of Pharmaceutical Industry, batch number 770423, the control drug isoniazid, mevalonate ADM (rifampicin) and Isobutylpiperazine force of daunorubicin, according to the dilution of the concentration were placed in the Valsalva tube. Medium: The modified Sutong semi-fluid medium, after preparation, were added to the drug containing Valsalva tube.